Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-selection study of dolutegravir-based first-line HIV therapy in treatment-naive adults
2009-010269-21Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of dolutegravir in Human immunodeficiency virus infection type 1 (4 arms), sponsored by ViiV Healthcare. Primary endpoint: Virologic response through Week 16. Started Apr 2009; status: completed.
02
Drugs
dolutegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-010269-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010269-21.